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Summary The expression of carcinoembryonic antigen (CEA) in gastric malignancies has been assessed
using a monoclonal antibody in an immunoperoxidase technique. Of 119 primary tumours examined,
92% reacted with the antibody. Metastases were available for 81 of the patients and 83% were CEA
positive. A noteworthy observation was the detection of malignant cells in the lymph nodes of two
patients, as a result of the presence of CEA, who were originally reported to be free of metastases. Of
those patients whose primary tumours expressed CEA, 86% had at least one CEA positive metastasis.
Two or more metastases were available from 60 of the patients and in 20% the secondaries were a
mixture of positive and negative for CEA. Consequently, the CEA status of a single lesion does not
enable confident prediction of expression in other metastases. In addition to variation between multiple
lesions removed from the same patient phenotypic diversity of expression was observed between tumour
cells of a given mass. Such distribution of the CEA detected by this monoclonal antibody may impose
certain restrictions on its application. However, the high frequency of expression by gastric cancers
indicate that it is a potentially useful antigen as a target for radiolocalisation or therapeutic agents.
Carcinoembryonic antigen (CEA) has been
extensively investigated over the past 15 years.
Much of the effort has been directed towards
measurement of serum and tissue levels in many
diseases, particularly gastrointestinal cancer.
Generally (N.I.H. Concensus Statement, 1981),
these studies have shown that blood levels
possess a limited role in tumour diagnosis and
are a relatively late indicator of disease in
tumour monitoring (Finlay & McArdle, 1983).
However, more recently attention has been
focused on the exploitation of the tumour-
associated properties of CEA for radiolocalisation
(Goldenberg et al., 1978a) and targeting of
tumoricidal agents (Rowland et al., 1982).
Whether or not this potential will be realised in
terms of clinical use will depend on several
factors. We feel that the most important of these
include the incidence of tumours which express
CEA and the degree and significance of variation
in antigen expression between patients' tumour
cells. Antigenic heterogeneity has been observed
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among several tumours in animal models and
human cell lines, but there have been few studies
in which primary and metastatic tumour samples
taken directly from patients have been compared.
In order to investigate the degree to which this
phenomenon occurs for CEA in gastric
malignancies and to assess the frequency of
expression, we have used a monoclonal antibody
to localise the antigen in a large series of
tumours.
Materials and methods
Patients and tissue specimens
Sections were cut from the stored, routine,
formalin fixed, paraffin embedded blocks of the
primaries and lymph nodes of the first 119
patients entered by the West Midlands into the
first British Stomach Cancer Group (BSCG)
Trial (Jones, 1981). Samples were available from
the primary tumours of all 119 patients and
from 81 of these who also had at least one
histologically confirmed lymph node metastasis.
Two hundred and fifty-seven lymph nodes were
assessed; 210 contained metastases.
© The Macmillan Press Ltd., 1984130 M.S. HOCKEY et al.
Immunoperoxidase technique
The two-stage indirect immunoperoxidase
technique as detailed by Ford et al. (1981) was
used with the following modifications. The first
antibody was a murine monoclonal anti-CEA
(Li1-285-14)* raised to CEA by established
procedures (Woodhouse, 1982 and Rowland et
al., 1982). It has been shown to lack reactivity
with normal skin, brain, breast, lung, liver, bile
duct, pancreas, kidney, prostate, testis, thyroid,
spleen and lymph node by immunocytochemistry
when used in a 1/1000 dilution of the unpurified
ascitic fluid (as used in the remainder of this
study). It binds to colonic and gastric tumours
as well as 6/11 ductal mammary carcinomas.
Some normal gastrointestinal and tonsillar
epithelia also bind the antibody (Woodhouse,
1982; Gatter et al., 1982). All foetal colonic
tissues tested have been positive. There was no
significant binding of this antibody to non-
specific cross-reacting antigen purified from
human lung in an enzyme-linked immunosorbent
assay (Woodhouse, 1982).
The second antibody was a horseradish
peroxidase conjugated rabbit antimouse
immunoglobulin (Dakopatts). Each pair of
sections was incubated with either a 1/1000
dilution of the first antibody or a 1/1000
dilution of P3-X63 Ag8 control ascitic fluid
(Bethesda Research Laboratories) as a negative
control and then with a 1/50 dilution of the
conjugated second antibody. Each batch of
sections processed included a pair of sections
from a colonic carcinoma, known to express CEA,
as a positive control.
Interpretation of staining
Each section was assessed for the number of
cells showing a positive reaction; intensity of
stain was not assessed. The results were classified
into 3 groups: one in which all cells were
negative for CEA (- group): one in which it
was considered that <5% of cells were positive
(+ or weakly positive group) and one in which
>5% of cells were considered to be positive
(+ + or strongly positive group). Where more
than one section of primary or more than one
metastasis was assessed the patient was scored
on the basis of the highest score achieved.
*This antibody was produced in a collaborative project
between Drs C.H.J. Ford, C.S. Woodhouse & C.E.
Newman, Surgical Immunology Unit, and Drs G.
Rowland & J. Corvalan, Eli Lilly Research.
Results
CEA staining in primary and metastatic gastric
carcinoma.
Primary tumours (92.4%, Table I) contained
some CEA varying from a few cells to almost
100% in many cases, though even in these latter
cases negative cells could almost always be
found; 61.3% were strongly positive (+ +).
Eighty-three percent of the patients with lymph
node metastases were found to be positive, rather
less than the primary tumours, but a greater
proportion (68%) were found to be strongly
positive (+ +). It was our impression that the
metastatic deposits were generally more
homogeneous in their CEA expression than the
primary tumours.
Table I
CEA status ofprimary andmetastatic gastric carcinoma
Total Tissue CEA status
Strongly Weakly
Positive Positive
++ + Negative
119 Primary 73 (61%) 37 (31%) 9 (8%)
81 Lymph
node 55 (68%) 12 (15%) 14 (17%)
Table H
Correlation of primaries and lymph node metastases
(81patients)
Lymph node metastases
Strongly Weakly
Positive Positive
+ + + Negative
Strongly
Positive 44 5 5
Weakly
Primaries Positive 11 3 5
+
Negative 0 4 4
Correlation between the CEA expression of
primary and metastatic tumours.
There is concordance between the CEA status of
primary tumours and their autologous metastases
in 63% of the patients (Table II); or 83% if theCEA EXPRESSION IN GASTRIC CARCINOMA 131
groups are considered simply as positive or
negative for CEA. However we found that in 5
patients (6.2%) with strongly positive (+ +)
primary tumours, and less surprisingly in 5
(6.2%) with weakly positive tumours (+) all
available metastases were negative for CEA.
Whilst 4 patients with apparently negative
primary tumours had at least one weakly
positive metastasis (+), no patient with a
negative primary had strongly positive metastases
(+ +).
Variation of CEA expression in the lymph node
metastases of an individual patient.
Samples were available from 60 patients who
had 2 or more metastases (range 2-13 mean 3.1)
(Table III). The pattern of CEA expression was
entirely consistent i.e. all the metastases were
strongly positive (+ +) or all were weakly
positive (+) or all were negative for CEA in
70%. In a further 10% all the metastases were
positive but a mixture of weakly (+) and
strongly (+ +) positive staining coexisted.
However an important finding was that 20% of
patients had a mixture of negatively and
positively, in some cases strongly positively,
staining metastases.
Table m
consistency ofCEA expression
Patients Total
Lymph nodes No ofmetastases
2 3 4 5 6 13
Primary All positive 15 13 4 2 2 1 37
Positive All negative 4 4 8
Mixed 2 3 3 1 9
Primary All positive 1 I
Negative All negative 2 2
Mixed 1 1 1 3
Staging.
Eleven of the patients studied were originally
reported by their own pathologist as being free
from lymph node metastases. However, on
staining for CEA, 2 patients were found to have
lymph nodes which contained scattered individual
cells which were clearly positive for CEA. In
addition small clumps of more obviously
malignant cells were found in the perinodal fat.
These were very obvious when stained for CEA
but were overlooked on the original examination
with H & E stain, though review of the H & E
sections using cytological criteria, viz. nuclear
pleomorphism, identified single and small groups
of malignant cells (H.T.). It could be argued that
the single cells are non-malignant mononuclear
cells, possibly containing ingested CEA, but this
type of clearly stained cell was only ever found
in conjunction with more obvious tumour, either
as in these 2 specific cases or in others which
were already reported as containing metastases.
In addition if mononuclear cells with
phagocytosed CEA were being identified we
would have expected single cells to occur
regularly in the uninvolved areas of nodes which
were only partially, but substantially, replaced by
tumour; this, however, was an uncommon
finding. In 47 other normal lymph nodes
examined no staining of any sort was seen nor
is any reactivity found in normal spleen. The
evidence strongly suggests that it is malignant
cells that have been identified.
Discussion
The overall rate of positivity in this study was
found to be 92% for primary tumours and 83%
for metastases. It is difficult to make a direct
comparison of these results with previously
published studies since to our knowledge there
have been no others in which a monoclonal
antibody has been used and most of those using
polyclonal antisera have examined relatively small
numbers of gastric tumours. One exception to
this was an immunofluorescence study of 150
gastric carcinomas (Lee et al., 1978) in which
62% were found to be "to a great extent
histologically positive." Also using an
immunofluorescence technique Ejeckam et al.
(1979) found that 90% of 29 carcinomas were
positive. Using an immunoperoxidase technique
CEA expression occurred in all of 18 (Skinner &
Whitehead, 1982) and 7 (Wagener et al., 1981)
gastric carcinomas. The latter authors also noted
that the staining was either patchy or restricted
to some single positive cells. Goldenberg et al.
(1978b), have reported that 5 of 14 gastric
carcinomas were positive, a significantly lower
proportion than the other studies. The high
proportion reported here may be due to
differences in sensitivity or specificity, i.e. our
test system may be more sensitive or our
antibody recognises a sub-species of CEA distinct
from that recognised by other workers.
Heterogeneity of CEA expression within lesions
has been previously reported in stomach tumours
(Ejeckam et al., 1979). We have confirmed this
and have also noted important differences of
CEA expression between separate lesions taken
from an individual patient.132 M.S. HOCKEY et al.
There are several possible reasons for these
observations. It is well known that gastric
tumours are histologically heterogeneous (Day,
1981) and ability to express CEA may be a
biochemical equivalent of the morphological
heterogeneity. Diversity of several phenotypic
characteristics seems to be a feature of many
neoplasms (Fidler & Hart, 1982) and it has been
suggested that antigen markers could be used as
an indicator of aggressive behaviour or
metastatic capacity. However, our results do not
support the notion that CEA identifies a
subpopulation of cells with greater metastatic
potential since the 81 patients with metastases
had 91% positive primaries and produced 83%
positive metastases, a difference which is even
less if only the strongly positive are considered,
giving 67% and 68% respectively - the expected
result if CEA and metastatic potential are
unrelated. Alternatively it has been shown that
CEA production by some cultured cells is
dependent upon the phase of cell growth
(Drewinko & Yang, 1976) and consequently CEA
expression may be related to the stage of the
cell cycle at which the cells were sampled; even
in our cases with near total staining a few cells
did not stain. The possibility must also be
considered that monoclonal antibodies may reveal
a greater degree of heterogeneity than polyclonal
antibodies as a result of a restriction of epitope
recognition (Rogers et al., 1981 and Primus et
al., 1983). Thus, 11-285-14 may detect a species
of CEA which is expressed by a certain fraction
of the cells and does not necessarily preclude
expression of different species of CEA by other
cells of heterogeneous tumour. The implications
of heterogeneous CEA expression for
immunodiagnosis and therapy will depend upon
the technique and agents employed. For
radiolocalisation and targeted therapy the
presence of negative cells in a tumour may not
matter provided that enough target antigen is
present to provide a tumour to normal tissue
differential. However, we have identified a
population of 20% of patients with mixed
positive and negative metastatic tumours in
whom failure of localisation would be expected.
Using a monoclonal antibody we have
demonstrated that CEA or a subspecies of CEA
is expressed by the majority of gastric
carcinomas and shows phenotypic heterogeneity
within and between different primary and
metastatic tumours. These results reveal that
CEA is not an ideal target antigen for gastric
cancer. Still, there is as yet no evidence of an
antigen associated with this disease which does
not suffer from the same disadvantages.
Consequently, we feel that the role of CEA as a
target for delivery of localising and therapeutic
agents deserves further investigation, possibly
using a combination of different antibodies to
overcome the problem of heterogeneity.
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